Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
850 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07639268 | Caregivers-Patients Support to Cope With Advanced-Cancer (CASA)(CASA) | enrolling by invitation | N/A | 124 | Ponce Medical School Foundation, Inc.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | not yet recruiting | Early Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 2 |
| Aug 26, 2026 |
| clinicaltrials |
| NCT00217737 | Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | completed | Phase 3 | 2,431 | National Cancer Institute (NCI)NIH | 5 | Aug 25, 2026 | clinicaltrials |
| NCT02176967 | Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma | active not recruiting | Phase 3 | 621 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | recruiting | Phase 3 | 1,780 | Children's Oncology GroupNETWORK | 9 | Aug 25, 2026 | clinicaltrials |
| NCT03126916 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | recruiting | Phase 3 | 750 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | recruiting | Phase 3 | 5,951 | Children's Oncology GroupNETWORK | 5 | Aug 25, 2026 | clinicaltrials |
| NCT04039607 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma(CheckMate 9DW) | completed | Phase 3 | 732 | Bristol-Myers SquibbINDUSTRY | 26 | Aug 25, 2026 | clinicaltrials |
| NCT04322318 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | recruiting | Phase 2 | 256 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT05235165 | Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | recruiting | Phase 3 | 62 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT06079671 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)(eVOLVECervical) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 19 | Aug 25, 2026 | clinicaltrials |
| NCT05074264 | Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico(CAMPO-101) | active not recruiting | N/A | 1,586 | University of California, San FranciscoOTHER | 2 | Aug 24, 2026 | clinicaltrials |
| NCT05554380 | Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 2 | Aug 24, 2026 | clinicaltrials |
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | active not recruiting | Phase 3 | 450 | National Cancer Institute (NCI)NIH | 3 | Aug 21, 2026 | clinicaltrials |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 199 | National Cancer Institute (NCI)NIH | 2 | Aug 21, 2026 | clinicaltrials |
| NCT04008030 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)(CheckMate 8HW) | active not recruiting | Phase 3 | 839 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 20, 2026 | clinicaltrials |
| NCT04936308 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent(SOLSTICE) | completed | Phase 3 | 453 | Janssen Research & Development, LLCINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT06651957 | Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)(ULACNet-104) | active not recruiting | — | 217 | University of California, San FranciscoOTHER | 3 | Aug 20, 2026 | clinicaltrials |
| NCT02521493 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | active not recruiting | Phase 3 | 280 | Children's Oncology GroupNETWORK | 6 | Aug 19, 2026 | clinicaltrials |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 352 | Children's Oncology GroupNETWORK | 19 | Aug 19, 2026 | clinicaltrials |
| NCT03937635 | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | recruiting | Phase 3 | 288 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 19, 2026 | clinicaltrials |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | recruiting | Phase 3 | 1,450 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 19, 2026 | clinicaltrials |
| NCT07090174 | CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 2 | Aug 19, 2026 | clinicaltrials |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment(EMERALD-2) | active not recruiting | Phase 3 | 908 | AstraZenecaINDUSTRY | 24 | Aug 14, 2026 | clinicaltrials |
| NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | terminated | Phase 1 | 226 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Aug 14, 2026 | clinicaltrials |
| NCT05510908 | Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC | completed | — | 460 | AIDS Malignancy ConsortiumNETWORK | 2 | Aug 14, 2026 | clinicaltrials |
| NCT03871257 | A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma | active not recruiting | Phase 3 | 165 | National Cancer Institute (NCI)NIH | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-01) | active not recruiting | Phase 3 | 510 | Olema Pharmaceuticals, Inc.INDUSTRY | 26 | Aug 13, 2026 | clinicaltrials |
| NCT00770809 | Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | completed | Phase 3 | 305 | National Cancer Institute (NCI)NIH | 2 | Aug 12, 2026 | clinicaltrials |
| NCT04164082 | Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | active not recruiting | Phase 2 | 161 | National Cancer Institute (NCI)NIH | 3 | Aug 11, 2026 | clinicaltrials |
| NCT04685135 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation(KRYSTAL-12) | active not recruiting | Phase 3 | 453 | Mirati Therapeutics Inc.INDUSTRY | 24 | Aug 11, 2026 | clinicaltrials |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)(CAMBRIA-2) | active not recruiting | Phase 3 | 5,511 | AstraZenecaINDUSTRY | 44 | Aug 10, 2026 | clinicaltrials |
| NCT03504644 | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 7, 2026 | clinicaltrials |
| NCT03997370 | Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol | active not recruiting | Phase 1 | 350 | NRG OncologyOTHER | 2 | Aug 7, 2026 | clinicaltrials |
| NCT05640102 | Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | recruiting | — | 111 | BeiGeneINDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | recruiting | Phase 3 | 880 | NRG OncologyOTHER | 3 | Aug 7, 2026 | clinicaltrials |
| NCT01547741 | Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer | completed | Phase 3 | 4,242 | NSABP Foundation IncNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT03253848 | Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia | active not recruiting | N/A | 202 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT03419234 | Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel | active not recruiting | Phase 2 | 223 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | recruiting | Phase 3 | 1,295 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 5, 2026 | clinicaltrials |
| NCT01169337 | Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | active not recruiting | Phase 3 | 226 | National Cancer Institute (NCI)NIH | 3 | Aug 4, 2026 | clinicaltrials |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | active not recruiting | Phase 3 | 712 | National Cancer Institute (NCI)NIH | 3 | Aug 4, 2026 | clinicaltrials |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | active not recruiting | Phase 3 | 994 | National Cancer Institute (NCI)NIH | 3 | Aug 4, 2026 | clinicaltrials |
| NCT04739800 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | active not recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 165 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma(EPCORE™FL-2) | active not recruiting | Phase 3 | 1,095 | GenmabINDUSTRY | 32 | Aug 4, 2026 | clinicaltrials |
| NCT06748222 | E-Mindfulness Approaches for Living After Breast Cancer(HEAL-ABC) | recruiting | Phase 3 | 402 | NRG OncologyOTHER | 2 | Aug 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials